General References | - Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH: Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res. 2000 Feb;6(2):390-6. [PubMed:10690515 ]
- Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM: Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000 Aug;6(8):3071-80. [PubMed:10955786 ]
- Nehra G, Andrews S, Rettig J, Gould MN, Haag JD, Howard SP, Thorne RG: Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats. Sci Rep. 2021 Mar 18;11(1):6351. doi: 10.1038/s41598-021-85293-4. [PubMed:33737566 ]
- Cho HY, Swenson S, Thein TZ, Wang W, Wijeratne NR, Marin-Ramos NI, Katz JE, Hofman FM, Schonthal AH, Chen TC: Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. doi: 10.1093/noajnl/vdaa160. eCollection 2020 Jan-Dec. [PubMed:33392507 ]
- Ravera M, Gabano E, Zanellato I, Rangone B, Perin E, Ferrari B, Bottone MG, Osella D: Cis,cis,trans-[Pt(IV)Cl2(NH3)2(perillato)2], a dual-action prodrug with excellent cytotoxic and antimetastatic activity. Dalton Trans. 2021 Mar 7;50(9):3161-3177. doi: 10.1039/d0dt04051g. Epub 2021 Feb 17. [PubMed:33595015 ]
|
---|